Dr Ivan Koychev, Associate Professor in Neuropsychiatry at Imperial College London, highlights the real opportunity: "The most encouraging evidence for GLP-1 therapies comes from epidemiology, showing reduced dementia incidence in people using these drugs. That suggests a preventive signal rather than an effect in treating established disease."
In other words, EVOKE asked: can we slow decline once symptoms appear? Answer: no. But the more important question might be: can we prevent dementia before symptoms start? That remains wide open.
As Ivan notes: "Science moves forward when we learn from every result, positive or negative, and keeps our focus on what matters most: better, evidence-based options for patients and families."
This is why rigorous trials - even those that don't meet their endpoints - are essential. They refine our hypotheses, clarify where to focus next, and remind us that timing of intervention may be as crucial as the intervention itself.
This article is worth a read 👇 https://zurl.co/ZFZpM